KSHV After an Organ Transplant: Should We Screen?
The incidence of Kaposi sarcoma (KS) related to Kaposi sarcoma-associated herpesvirus (KSHV/HHV-8) after organ transplantation is 500–1,000 times greater than in the general population, and its occurrence is associated with immunosuppressive therapy. The reported incidence of posttransplant KS ranges from 0.5% to 5%, depending on the patient’s country of origin and the type of organ received, mainly after renal transplantation. Posttransplant KS is caused by two possible mechanisms: KSHV reactivation in patients who were infected before the graft and KSHV contamination from the infected organ’s donor to the recipient. KSHV reactivation appears to play a greater role in the risk of KS than incident infections. However, some studies, with findings based not only on serological data but also on molecular tracing of the viral infection, have shown that organ-related transmission of KSHV could be more common than previously thought and associated in some cases with severe KSHV-related disease. Precise estimates of KSHV seroprevalence in the organ donor and recipient populations in different countries are lacking. However, studies have reported seroprevalences among donors and recipients that are similar to those among the general population of the country considered. Many studies have suggested the potential utility of screening of KSHV antibodies among organ donors and recipients. However, to date the results of these studies have argued in favor of KSHV screening, even in low-KSHV infection prevalence countries, not to exclude the graft but to have the KSHV status information in order to have the opportunity to monitor, clinically and biologically, patients at risk for KSHV-related disease development. The detection of KSHV antibodies could be done in the days after the transplantation and the results transmitted to the physicians retrospectively. In conclusion, the question of screening donors and recipients for KSHV, even in low-KSHV infection prevalence countries, is still debated, and prospective studies are needed to evaluate the benefit of pre- and posttransplantation strategies.
KeywordsTransplant Recipient Liver Transplant Recipient Castleman Disease KSHV Infection Latent Nuclear Antigen
Unable to display preview. Download preview PDF.
- Andreoni M, Goletti D, Pezzotti P, Pozzetto A, Monini P, Sarmati L, Farchi F, Tisone G, Piazza A, Pisani F, Angelico M, Leone P, Citterio F, Ensoli B, Rezza G (2001) Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi’s sarcoma in renal and liver transplant recipients. J Infect 43, 195–9PubMedCrossRefGoogle Scholar
- Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, Manganaro D, Fasan M, Moroni M, Galli M, Parravicini C (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98, 3473–5PubMedCrossRefGoogle Scholar
- Farge D, Lebbe C, Marjanovic Z, Tuppin P, Mouquet C, Peraldi MN, Lang P, Hiesse C, Antoine C, Legendre C, Bedrossian J, Gagnadoux MF, Loirat C, Pellet C, Sheldon J, Golmard JL, Agbalika F, Schulz TF (1999) Human herpes virus-8 and other risk factors for Kaposi’s sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d’ Ile de France (GCIF). Transplantation 67, 1236–42PubMedCrossRefGoogle Scholar
- Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, Phair J, Detels R, Parry P, Chang Y, Moore PS (1996a) Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med 335, 233–41PubMedCrossRefGoogle Scholar
- Gomezdos Santos V, Burgos Revilla FJ, Pascual Santos J, Orofino Ascunce L, Fernandez-Juarez G, Crespo Martinez L, Clemente Ramos L, Carrera Puerta C, Marcen Letosa R, Escudero Barrilero A, Ortuno Mirete J (1997) [Neoplasm prevalence in renal transplantation]. Arch Esp Urol 50, 267–73; discussion 273–4Google Scholar
- Hiesse C, Larue JR, Kriaa F, Blanchet P, Bellamy J, Benoit G, Charpentier B (1995) Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients. Transplant Proc 27, 2450–1PubMedGoogle Scholar
- Kaufman DB, Leventhal JR, Stuart J, Abecassis MM, Fryer JP, Stuart FP (1999) Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. Transplantation 67, 586–93PubMedCrossRefGoogle Scholar
- Marcelin AG, Roque-Afonso AM, Hurtova M, Dupin N, Tulliez M, Sebagh M, Arkoub ZA, Guettier C, Samuel D, Calvez V, Dussaix E (2004) Fatal disseminated Kaposi’s sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl 10, 295–300PubMedCrossRefGoogle Scholar
- Montagnino G, Lorca E, Tarantino A, Bencini P, Aroldi A, Cesana B, Braga M, Lonati F, Ponticelli C (1996) Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transplant 10, 461–9PubMedGoogle Scholar
- Parravicini C, Olsen SJ, Capra M, Poli F, Sirchia G, Gao SJ, Berti E, Nocera A, Rossi E, Bestetti G, Pizzuto M, Galli M, Moroni M, Moore PS, Corbellino M (1997) Risk of Kaposi’s sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi’s sarcoma patients. Blood 90, 2826–9PubMedGoogle Scholar
- Pellet C, Chevret S, Frances C, Euvrard S, Hurault M, Legendre C, Dalac S, Farge D, Antoine C, Hiesse C, Peraldi MN, Lang P, Samuel D, Calmus Y, Agbalika F, Morel P, Calvo F, Lebbe C (2002) Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in posttransplantation Kaposi sarcoma. J Infect Dis 186, 110–3PubMedCrossRefGoogle Scholar
- Schatz O, Monini P, Bugarini R, Neipel F, Schulz TF, Andreoni M, Erb P, Eggers M, Haas J, Butto S, Lukwiya M, Bogner JR, Yaguboglu S, Sheldon J, Sarmati L, Goebel FD, Hintermaier R, Enders G, Regamey N, Wernli M, Sturzl M, Rezza G, Ensoli B (2001) Kaposi’s sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. J Med Virol 65, 123–32PubMedCrossRefGoogle Scholar
- Zhu L, Wang R, Sweat A, Goldstein E, Horvat R, Chandran B (1999) Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Virology 256, 381–92PubMedCrossRefGoogle Scholar
- Zong JC, Ciufo DM, Alcendor DJ, Wan X, Nicholas J, Browning PJ, Rady PL, Tyring SK, Orenstein JM, Rabkin CS, Su IJ, Powell KF, Croxson M, Foreman KE, Nickoloff BJ, Alkan S, Hayward GS (1999) High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi’s sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations. J Virol 73, 4156–70PubMedGoogle Scholar